Anurag Sharma, PhD

Anurag joined Food and Drug Administration (FDA)/CBER/OTAT as a gene therapy product reviewer in October 2018 and conducts scientific review of CMC data to assess safety and quality of investigational gene therapy products. Anurag’s educational background includes a DVM and Masters in Animal Biotechnology from India. Thereafter, Anurag pursued his PhD in Molecular Virology at Purdue University, West Lafayette, IN, where he worked on the development and characterization of novel adenoviral vectors for gene delivery applications. After his doctoral degree, Anurag joined Weill Cornell Medicine (WCM), New York as a postdoctoral associate and subsequently as an Assistant Professor of Research. At WCM, Anurag continued his research to design innovative strategies to further improve adenoviral vectors and to develop vaccines against some of pediatric respiratory infections with no approved vaccines. Anurag also holds Regulatory Affairs Certification (RAC) offered by Regulatory Affairs Professionals Society (RAPS).